日本抗真菌药物市场报告（按药物类别（唑类、棘白菌素类、多烯类、烯丙胺类及其他）、适应症（皮癣菌病、曲霉病、念珠菌病及其他）和地区划分，2026-2034年）

Japan Antifungal Drugs Market Report by Drug Classe (Azoles, Echinocandins, Polyenes, Allylamines, and Others), Indication (Dermatophytosis, Aspergillosis, Candidiasis, Others), and Region 2026-2034

出版日期: 2026年01月01日 | 出版商:

IMARC | 英文 115 Pages | 商品交期: 5-7个工作天内

价格

简介目录

2025年，日本抗真菌药物市场规模达11.3亿美元。展望未来， IMARC Group预计到2034年，该市场规模将达到16.4亿美元，2026年至2034年间的复合年增长率（CAGR）为4.24%。真菌感染病例的增加，归因于多种因素，例如免疫功能低下人群的增加、人口老化以及免疫抑制剂的广泛使用等，这些因素正在推动市场成长。

本报告解答的关键问题：

日本抗霉菌药物市场目前表现如何？未来几年又将如何发展？
新冠疫情对日本抗霉菌药物市场产生了哪些影响？
日本抗真菌药物市场按药物类别分類的组成是怎样的？
日本抗霉菌药物市场依适应症分類的组成是怎样的？
日本抗真菌药物市场价值链的各个阶段有哪些？
日本抗真菌药物的关键驱动因素和挑战是什么？
日本抗霉菌药物市场的结构是怎么样的？主要参与者有哪些？
日本抗霉菌药物市场的竞争程度如何？

Japan antifungal drugs market size reached USD 1.13 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 1.64 Billion by 2034, exhibiting a growth rate (CAGR) of 4.24% during 2026-2034. The increasing cases of fungal infections, attributed to several factors, such as a growing population of immunocompromised individuals, aging people, the widespread use of immunosuppressive drug, etc., are driving the market.

Antifungal drugs are pharmaceutical compounds designed to combat fungal infections in humans, animals, and plants. Fungal infections can range from mild skin conditions to severe, life-threatening systemic illnesses. These drugs work by targeting various aspects of fungal cell growth and function, inhibiting their ability to replicate and spread. There are several classes of antifungal drugs, including azoles, polyenes, echinocandins, and allylamines. Azoles, such as fluconazole and itraconazole, interfere with fungal cell membrane synthesis. Polyenes, like amphotericin B, disrupt fungal cell membranes directly. Echinocandins, including caspofungin, inhibit cell wall formation. Allylamines, such as terbinafine, interfere with fungal enzyme activity. Choosing the appropriate antifungal drug depends on the type and severity of the infection, as well as the patient's health status. Some antifungals are available over-the-counter for topical use, while others require a prescription for systemic infections. It's crucial to use these drugs as prescribed to ensure effectiveness and minimize the risk of drug-resistant fungal strains emerging.

Japan Antifungal Drugs Market Trends:

The antifungal drugs market in Japan is poised for significant growth, primarily due to several interconnected factors. Firstly, the rising incidence of fungal infections serves as a crucial driver. As fungal pathogens become more resistant, the demand for innovative antifungal therapies intensifies. Moreover, the growing elderly population, often with compromised immune systems, increases susceptibility to fungal infections, further propelling market expansion. Secondly, advancements in medical research and biotechnology have paved the way for novel antifungal drug development. Breakthroughs in understanding fungal biology and the discovery of new drug targets have led to a steady influx of innovative therapies. Consequently, pharmaceutical companies are investing heavily in R&D, fostering market growth. Additionally, the rising support from various governments and healthcare organizations in the form of funding and favorable policies to control the spread of fungal infections is expected to drive the antifungal drugs market in Japan during the forecast period.

Japan Antifungal Drugs Market Segmentation:

Drug Class Insights:

Azoles
- Voriconazole (Vfend)
- Posaconazole (Noxafil)
- Clotrimazole (Canesten)
- Isavuconazole (Cresemba)
- Others
Echinocandins
- Caspofungin (Cancidas)
- Micafungin (Mycamine/ Funguard)
- Others
Polyenes
- Amphotericin (AmBisome)
- Others
Allylamines
- Terbinafine (Lamisil)
- Others
Others

Indication Insights:

Dermatophytosis
Aspergillosis
Candidiasis
- Invasive Candidiasis
- Vulvovaginal Candidiasis (VVC)
- Mouth/Throat/Esophageal Candidiasis
- Others
Others

Regional Insights:

Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan antifungal drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan antifungal drugs market?
What is the breakup of the Japan antifungal drugs market on the basis of drug class?
What is the breakup of the Japan antifungal drugs market on the basis of indication?
What are the various stages in the value chain of the Japan antifungal drugs market?
What are the key driving factors and challenges in the Japan antifungal drugs?
What is the structure of the Japan antifungal drugs market and who are the key players?
What is the degree of competition in the Japan antifungal drugs market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Antifungal Drugs Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Antifungal Drugs Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Antifungal Drugs Market - Breakup by Drug Class

6.1 Azoles
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Segmentation
  - 6.1.3.1 Voriconazole (Vfend)
  - 6.1.3.2 Posaconazole (Noxafil)
  - 6.1.3.3 Clotrimazole (Canesten)
  - 6.1.3.4 Isavuconazole (Cresemba)
  - 6.1.3.5 Others
- 6.1.4 Market Forecast (2026-2034)
6.2 Echinocandins
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Segmentation
  - 6.2.3.1 Caspofungin (Cancidas)
  - 6.2.3.2 Micafungin (Mycamine/ Funguard)
  - 6.2.3.3 Others
- 6.2.4 Market Forecast (2026-2034)
6.3 Polyenes
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2020-2025)
- 6.3.3 Market Segmentation
  - 6.3.3.1 Amphotericin (AmBisome)
  - 6.3.3.2 Others
- 6.3.4 Market Forecast (2026-2034)
6.4 Allylamines
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2020-2025)
- 6.4.3 Market Segmentation
  - 6.4.3.1 Terbinafine (Lamisil)
  - 6.4.3.2 Others
- 6.4.4 Market Forecast (2026-2034)
6.5 Others
- 6.5.1 Historical and Current Market Trends (2020-2025)
- 6.5.2 Market Forecast (2026-2034)

7 Japan Antifungal Drugs Market - Breakup by Indication

7.1 Dermatophytosis
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Forecast (2026-2034)
7.2 Aspergillosis
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Forecast (2026-2034)
7.3 Candidiasis
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2020-2025)
- 7.3.3 Market Segmentation
  - 7.3.3.1 Invasive Candidiasis
  - 7.3.3.2 Calcium Carbonate
  - 7.3.3.3 Vulvovaginal Candidiasis (VVC)
  - 7.3.3.4 Mouth/Throat/Esophageal Candidiasis
  - 7.3.3.5 Others
- 7.3.4 Market Forecast (2026-2034)
7.4 Others
- 7.4.1 Historical and Current Market Trends (2020-2025)
- 7.4.2 Market Forecast (2026-2034)

8 Japan Antifungal Drugs Market - Breakup by Region

8.1 Kanto Region
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Breakup by Drug Class
- 8.1.4 Market Breakup by Indication
- 8.1.5 Key Players
- 8.1.6 Market Forecast (2026-2034)
8.2 Kansai/Kinki Region
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Breakup by Drug Class
- 8.2.4 Market Breakup by Indication
- 8.2.5 Key Players
- 8.2.6 Market Forecast (2026-2034)
8.3 Central/ Chubu Region
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2020-2025)
- 8.3.3 Market Breakup by Drug Class
- 8.3.4 Market Breakup by Indication
- 8.3.5 Key Players
- 8.3.6 Market Forecast (2026-2034)
8.4 Kyushu-Okinawa Region
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2020-2025)
- 8.4.3 Market Breakup by Drug Class
- 8.4.4 Market Breakup by Indication
- 8.4.5 Key Players
- 8.4.6 Market Forecast (2026-2034)
8.5 Tohoku Region
- 8.5.1 Overview
- 8.5.2 Historical and Current Market Trends (2020-2025)
- 8.5.3 Market Breakup by Drug Class
- 8.5.4 Market Breakup by Indication
- 8.5.5 Key Players
- 8.5.6 Market Forecast (2026-2034)
8.6 Chugoku Region
- 8.6.1 Overview
- 8.6.2 Historical and Current Market Trends (2020-2025)
- 8.6.3 Market Breakup by Drug Class
- 8.6.4 Market Breakup by Indication
- 8.6.5 Key Players
- 8.6.6 Market Forecast (2026-2034)
8.7 Hokkaido Region
- 8.7.1 Overview
- 8.7.2 Historical and Current Market Trends (2020-2025)
- 8.7.3 Market Breakup by Drug Class
- 8.7.4 Market Breakup by Indication
- 8.7.5 Key Players
- 8.7.6 Market Forecast (2026-2034)
8.8 Shikoku Region
- 8.8.1 Overview
- 8.8.2 Historical and Current Market Trends (2020-2025)
- 8.8.3 Market Breakup by Drug Class
- 8.8.4 Market Breakup by Indication
- 8.8.5 Key Players
- 8.8.6 Market Forecast (2026-2034)

9 Japan Antifungal Drugs Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Product Portfolio
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Product Portfolio
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Product Portfolio
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Product Portfolio
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Product Portfolio
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Antifungal Drugs Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis